Wednesday, September 18, 2013

Wanbang Biopharma gets CFDA nod for conducting clinical trial on third generation Insulin Analogue

Wanbang Biopharmaceuticals, a subsidiary of Shanghai Fosun Pharma has received CFDA nod to initiate clinical trials of a third-generation insulin analogue, Lispro. Lispro is a recombinant insulin that is designed to be fast-acting, with a relatively short duration of action, usually taken just before, or just after mealtimes. In China, only Lilly and Gan & Lee offer Lispro-class insulin drugs. 

Enter your email address:


Delivered by FeedBurner